Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RMC-9805 · 1 trial · 4 indications
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs, and vital signs
Number of participants with Dose Limiting Toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| RMC-9805 monotherapy arm | EXPERIMENTAL | Dose exploration and dose expansion |
| RMC-9805 plus RMC-6236 combination arm | EXPERIMENTAL | Dose exploration and dose expansion |
| Name | Type | Description |
|---|---|---|
| RMC-9805 | DRUG | Oral Tablets |
| RMC-6236 | DRUG | Oral Tablets |
Inclusion Criteria: * Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation * Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage * ECOG performance status 0 or 1 * Adequate ...
RMC-9805 is an investigational small molecule being developed for the treatment of non-small cell lung cancer (NSCLC). It is also being studied in other KRAS G12D-mutant solid tumors, including colorectal cancer, pancreatic ductal adenocarcinoma, and advanced solid tumors. The drug is currently in Phase 1 clinical development.
RMC-9805 targets RAS, a protein that is frequently mutated in cancer. Specifically, the drug is being studied in patients with KRAS G12D-mutant solid tumors. By targeting RAS, RMC-9805 aims to interfere with cancer cell growth and survival pathways.
RMC-9805 is being developed by Revolution Medicines, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol RVMD. The company is conducting clinical trials to evaluate the safety and efficacy of RMC-9805 in patients with KRAS G12D-mutant solid tumors.
RMC-9805 is in Phase 1 clinical development. The drug is investigational and has not been approved by the FDA. It is currently being evaluated in a Phase 1 study to assess its safety, tolerability, and preliminary efficacy in patients with KRAS G12D-mutant solid tumors.
RMC-9805 is being studied in a Phase 1 clinical trial with the identifier NCT06040541. This trial is recruiting participants with KRAS G12D-mutant solid tumors, including non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The study is being conducted in the United States and has an enrollment target of 604 participants.